JMJD1A, H3K9me1, H3K9me2 and ADM expression as prognostic markers in oral and oropharyngeal squamous cell carcinoma

Lucas de Lima Maia, Gabriela Tonini Peterle, Marcelo dos Santos, Leonardo Oliveira Trivilin, Suzanny Oliveira Mendes, Mayara Mota de Oliveira, Joaquim Gasparini dos Santos, Elaine Stur, Lidiane Pignaton Agostini, Cinthia Vidal Monteiro da Silva Couto, Juliana Dalbó, Aricia Leone Evangelista Monteiro de Assis, Anderson Barros Archanjo, Ana Maria Da Cunha Mercante, Rossana Veronica Mendoza Lopez, Fábio Daumas Nunes, Marcos Brasilino de Carvalho, Eloiza Helena Tajara, Iúri Drumond Louro and Adriana Madeira Álvares-da-Silva

PLOS ONE, 2018, vol. 13, issue 3, 1-16

Abstract: Aims: Jumonji Domain-Containing 1A (JMJD1A) protein promotes demethylation of histones, especially at lysin-9 of di-methylated histone H3 (H3K9me2) or mono-methylated (H3K9me1). Increased levels of H3 histone methylation at lysin-9 (H3K9) is related to tumor suppressor gene silencing. JMJD1A gene target Adrenomeduline (ADM) has shown to promote cell growth and tumorigenesis. JMJD1A and ADM expression, as well as H3K9 methylation level have been related with development risk and prognosis of several tumor types. Methods and results: We aimed to evaluate JMJD1A, ADM, H3K9me1 and H3K9me2expression in paraffin-embedded tissue microarrays from 84 oral and oropharyngeal squamous cell carcinoma samples through immunohistochemistry analysis. Our results showed that nuclear JMJD1A expression was related to lymph node metastasis risk. In addition, JMJD1A cytoplasmic expression was an independent risk marker for advanced tumor stages. H3K9me1 cytoplasmic expression was associated with reduced disease-specific death risk. Furthermore, high H3K9me2 nuclear expression was associated with worse specific-disease and disease-free survival. Finally, high ADM cytoplasmic expression was an independent marker of lymph node metastasis risk. Conclusion: JMJD1A, H3K9me1/2 and ADM expression may be predictor markers of progression and prognosis in oral and oropharynx cancer patients, as well as putative therapeutic targets.

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194884 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 94884&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0194884

DOI: 10.1371/journal.pone.0194884

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().